Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

  • Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m. ET in Boston
  • 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025, at 1:30 p.m. ET in Boston
  • H.C. Wainwright 27 th Annual Global Investment Conference on Monday, September 8, 2025, at 10:30 a.m. ET in New York

The live webcasts will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, BEAM has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. BEAM's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that BEAM is using to advance a diversified portfolio of base editing programs. BEAM is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BEAM
The Conversation (0)
Angkor Resources Advances Community Development In Ratanakiri, Cambodia

Angkor Resources Advances Community Development In Ratanakiri, Cambodia

(TheNewswire)

GRANDE PRAIRIE, ALBERTA TheNewswire - (September 18, 2025): Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") proudly announces  its continuing community development program with basic infrastructure for transportation improvements.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
  Golden Mile Resources

Further Highly Encouraging Results from Pearl Copper Project in Arizona, USA

Golden Mile Resources Ltd (“Golden Mile”; “the Company”; ASX: “G88”) is pleased to announce the portable X-Ray Fluorescent (pXRF) results from the preliminary field mapping at the Ford Prospect, contained within the Pearl Copper Project (“the Project”). The polymetallic Ford Mine mineralisation is exposed at the surface within an eight-metre wide fault zone. Within this zone is visible copper mineralisation within a broader, intensely iron oxide alteration zone.

Keep reading...Show less
Pan Asia Metals

RK Lithium Project - KT East Lithium Prospect

Abundant Lepidolite Pegmatite Zone Identified – 1.5km x 500m

Battery and critical metals explorer and developer Pan Asia Metals Limited (ASX: PAM) (‘PAM’ or ‘the Company’) is pleased to report that field work at the KT East Lithium Prospect continues to deliver strong results and expand the potential for the prospect.

Keep reading...Show less
OUTBACK GOLDFIELDS DEFINES MULTIPLE NEW GOLD TARGETS AT THE GLENFINE PROJECT, VICTORIA

OUTBACK GOLDFIELDS DEFINES MULTIPLE NEW GOLD TARGETS AT THE GLENFINE PROJECT, VICTORIA

(TSX.V: OZ, OTCQB: OZBKF, FSE: S600)

Outback Goldfields Corp . (the " Company " or " Outback ") (TSXV: OZ) (OTCQB: OZBKF) is pleased to provide an update on exploration activities across its Glenfine project in the heart of the Victorian goldfields of Australia .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News